SL Science Holding Limited (SLBT)
SLBT trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | SLBT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | Taiwan |
| IPO year | Not reported by the screener |
| SEC CIK | 0002070534 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | Cayman Islands |
Financials
New registrant: no annual report filed under this company yet.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raise substantial doubt about its ability to continue as a going concern." | 20-F 2026-06-18 |
| Cash and burn | no XBRL financials | None on EDGAR |
| Shares outstanding | No cover-page share count in XBRL | None on EDGAR |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | ARK PRO CPA & CO, Hong Kong, China | PCAOB Form AP 2026-07-14 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-08-14 |
| Latest annual report ANNUAL REPORT | 20-F | 2026-06-18 |
| Latest quarterly / interim FORM 6-K | 6-K | 2026-11-03 |
Source: SEC EDGAR submissions feed, 45 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -22.5% |
| 1 month | -52.5% |
| 3 months | -73.2% |
| Year to date | -93.1% |
| 1 year | -93.0% |
| From 52-week high | -94.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| IRLA | IRulya Therapeutics Inc. | $37.36 | -6.13% | $405.0M |
| TECX | Tectonic Therapeutic Inc. | $20.98 | -0.76% | $418.5M |
| TVGN | Tevogen Inc. | $6.22 | +3.67% | $422.2M |
| ALEC | Alector Inc. | $2.57 | +1.18% | $382.6M |
| FENC | Fennec Pharmaceuticals Inc. | $12.76 | +9.81% | $450.5M |
| CADL | Candel Therapeutics Inc. | $5.81 | -6.29% | $455.8M |
| CCCC | C4 Therapeutics Inc. | $2.65 | -3.99% | $348.0M |
| RGNX | REGENXBIO Inc. | $7.32 | -4.19% | $484.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier